DK2061485T3 - EV576-peptider til anvendelse ved behandling af Guillain-Barré-syndrom - Google Patents

EV576-peptider til anvendelse ved behandling af Guillain-Barré-syndrom

Info

Publication number
DK2061485T3
DK2061485T3 DK07804199.3T DK07804199T DK2061485T3 DK 2061485 T3 DK2061485 T3 DK 2061485T3 DK 07804199 T DK07804199 T DK 07804199T DK 2061485 T3 DK2061485 T3 DK 2061485T3
Authority
DK
Denmark
Prior art keywords
guillain
peptides
treatment
barré syndrome
barré
Prior art date
Application number
DK07804199.3T
Other languages
English (en)
Inventor
John Hamer
Original Assignee
Varleigh Immuno Pharm Vip Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Varleigh Immuno Pharm Vip Ltd filed Critical Varleigh Immuno Pharm Vip Ltd
Application granted granted Critical
Publication of DK2061485T3 publication Critical patent/DK2061485T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK07804199.3T 2006-09-08 2007-09-10 EV576-peptider til anvendelse ved behandling af Guillain-Barré-syndrom DK2061485T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0617734.9A GB0617734D0 (en) 2006-09-08 2006-09-08 Method of treating peripheral nerve disorders
PCT/GB2007/003401 WO2008029167A1 (en) 2006-09-08 2007-09-10 Method of treating peripheral nerve disorders

Publications (1)

Publication Number Publication Date
DK2061485T3 true DK2061485T3 (da) 2012-11-19

Family

ID=37232629

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07804199.3T DK2061485T3 (da) 2006-09-08 2007-09-10 EV576-peptider til anvendelse ved behandling af Guillain-Barré-syndrom

Country Status (11)

Country Link
US (4) US9211312B2 (da)
EP (1) EP2061485B1 (da)
JP (1) JP5557528B2 (da)
AU (1) AU2007293239B2 (da)
CA (1) CA2662715C (da)
DK (1) DK2061485T3 (da)
ES (1) ES2397900T3 (da)
GB (1) GB0617734D0 (da)
NZ (1) NZ575461A (da)
PL (1) PL2061485T3 (da)
WO (1) WO2008029167A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
LT3028716T (lt) * 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
CA2785612C (en) 2010-01-08 2019-09-10 Varleigh Immuno Pharmaceuticals (Vip) Ltd. Ev576 for use in the treatment of viral infections of the respiratory tract
KR102149028B1 (ko) 2012-02-20 2020-08-27 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 폴리펩티드
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
WO2016198133A1 (en) * 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
GB201602802D0 (en) 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
IL263481B2 (en) 2016-06-14 2024-06-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
DK3411400T3 (da) 2017-04-03 2021-10-11 Inflarx Gmbh Behandling af inflammatoriske sygdomme med hæmmere af c5a-aktivitet
JP7209637B2 (ja) 2017-04-21 2023-01-20 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 自己免疫性水疱症の治療のためのコバーシン
AU2018286754A1 (en) 2017-06-23 2019-12-19 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5A activity
AU2018383751B2 (en) 2017-12-13 2025-05-08 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
JP7629394B2 (ja) 2018-09-10 2025-02-13 ヴォリューション イミュノ ファーマシューティカルズ エスエイ リウマチ性疾患の治療に使用するためのコバーシン
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
JP2023503776A (ja) 2019-09-27 2023-02-01 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 造血幹細胞移植後の血栓性微小血管症（ｈｓｃｔ－ｔｍａ）の治療方法
AU2020438234A1 (en) 2020-03-27 2022-09-29 Inflarx Gmbh Inhibitors of C5a for the treatment of corona virus infection
TW202208427A (zh) 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071096B2 (en) * 2002-01-25 2011-12-06 G2 Therapies Ltd Anti-C5aR antibodies and uses thereof
ITMI20021527A1 (it) * 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US7884188B2 (en) * 2003-06-02 2011-02-08 Varleigh Immuno Pharmaceuticals (Vip) Ltd Complement inhibitors
CA2579635A1 (en) * 2003-09-10 2005-03-17 Baxter International Inc. Peptides that inhibit complement activation
EP1739078A1 (de) * 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
WO2008030505A2 (en) * 2006-09-05 2008-03-13 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders

Also Published As

Publication number Publication date
CA2662715C (en) 2018-04-03
NZ575461A (en) 2011-11-25
EP2061485A1 (en) 2009-05-27
AU2007293239B2 (en) 2012-07-05
ES2397900T3 (es) 2013-03-12
JP5557528B2 (ja) 2014-07-23
WO2008029167A1 (en) 2008-03-13
US20160166641A1 (en) 2016-06-16
EP2061485B1 (en) 2012-08-22
AU2007293239A1 (en) 2008-03-13
US20190117730A1 (en) 2019-04-25
GB0617734D0 (en) 2006-10-18
US20220249608A1 (en) 2022-08-11
US9211312B2 (en) 2015-12-15
US20100111929A1 (en) 2010-05-06
PL2061485T3 (pl) 2013-03-29
CA2662715A1 (en) 2008-03-13
JP2010502686A (ja) 2010-01-28

Similar Documents

Publication Publication Date Title
DK2310034T3 (da) Peptider til behandling af beta-amyloidose
DK2205257T3 (da) Doseringsforskrifter for LAG-3Ig (IMP321) til anvendelse ved behandling af cancer
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
DK2781593T3 (da) Fremgangsmåde til behandling af methanemissioner
CY2016017I1 (el) Συνθεση για θεραπεια πνευμονικης υπερτασης
DK3567035T3 (da) N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer
FR2896407B3 (fr) Ambulateur
DK1877232T3 (da) Fremgangsmåde til behandling af træoverflader
DK3424932T3 (da) Bronophthalider til terapeutisk anvendelse
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
PL2061485T3 (pl) Peptydy EV576 do zastosowania w leczeniu zespołu Guillaina-Barrégo
DK2478907T3 (da) Sammensætninger til behandling af kræft
DK2100614T3 (da) Antistof mod PDGFR-alfa til anvendelse ved behandlingen af tumorer
ATE477312T1 (de) Flüssigkeitshärtung
EP2217064A4 (en) NEW VACCINES AGAINST SEVERAL SUBTYPES OF THE INFLUENZAVIRUS
DK2200600T3 (da) Neramexan til anvendelse ved behandlingen af subakut tinnitus
DK2216021T3 (da) Farmaceutisk sammensætning til behandling af overaktiv blære
DK2114386T3 (da) Farmaceutisk sammensætning til behandling af diabeteskomplikationer
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK2209784T3 (da) Forbindelser til behandling af hepatitis C
DK2152610T3 (da) Dampindeslutning
DK2032551T3 (da) Antitumorale dihydropyran-2-on-forbindelser
DK2323644T3 (da) N-substituerede benzenpropanamid- eller benzenpropenamidderivater til anvendelse ved behandlingen af smerte
DK2124946T3 (da) Anvendelse af N-methylpyridiniumderivater til hepatobeskyttelse
DK1989189T3 (da) Adsorbenter til proteinoprensning